ICG vs Blue Patent for TAD in cN1 Breast Carcinoma After Neoadjuvant Chemotherapy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorHospital Universitari de Bellvitge
About this trial
To validate the use of ICG as a tracer during TAD in patients with cN1 breast carcinoma after neoadjuvant chemotherapy.
Eligibility criteria
Qualifiers
Breast cancer cN+ patients who undergo neadjuvant treatment.
Disqualifiers
Patients in whom there is a contraindication for the use of ICG.
Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.
Trial design
Treatments tested in this trial
- Targeted axillary dissection (TAD) by ICG
- Targeted axillary dissection (TAD) by Blue patent
Treatment groups
43 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov